造血幹細胞移植市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、適應症、應用、最終用戶、地區和競爭格局分類），2021-2031年

全球造血幹細胞移植市場預計將從 2025 年的 30.9 億美元成長到 2031 年的 46.2 億美元，複合年成長率為 6.93%。

此治療領域涉及幹細胞輸注療法，旨在恢復免疫力缺乏或骨髓惡性腫瘤患者的骨髓功能。推動這一領域發展的關鍵因素包括全球血液癌症（如多發性骨髓瘤和白血病）發病率的不斷上升，以及供體配型技術的進步，這些進步提高了異基因移植的成功率。根據世界骨髓捐贈者協會（WMDA）2024年的數據，全球骨髓捐贈者登記網路目前涵蓋超過4430萬份臍帶血和志願者捐贈者，顯著擴大了無親屬捐贈者患者的配型途徑。

儘管取得了這些積極進展，但移植後併發症的高風險，尤其是移植物抗宿主疾病（GVHD），仍然是市場推廣的一大障礙。在這種情況下，供體細胞會侵襲受體組織，需要昂貴且長期的醫療管理，對患者的生活品質產生負面影響。因此，這些臨床風險和相關成本阻礙了該技術的廣泛應用，尤其是在醫療資源有限的情況下。

市場促進因素

造血幹細胞移植的主要促進因素是全球骨髓惡性腫瘤發生率的不斷上升。進行性血液系統癌症發生率的上升推動了對根治性骨髓重建的臨床需求，進而導致成熟醫療機構和新興醫療機構的移植手術量不斷增加。美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告預測，美國將新增66,890例白血病病例，凸顯了有效移植方案的緊迫性。不斷擴大的患者群體要求加強移植基礎設施建設，並促使捐贈組織擴大移植能力。此外，歐洲血液和骨髓移植協會（EBMT）於2025年2月發布的《2023年造血細胞移植和細胞治療報告》指出，2023年歐洲醫療中心進行的移植手術數量將達到47,731例，進一步證實了該手術的強勁發展勢頭。

同時，不匹配和半匹配供體移植技術的重大進步正在消除市場擴張的傳統障礙。移植後Cyclophosphamide通訊協定的引入顯著提高了部分匹配供體的安全性，使其惠及此前無法獲得完全匹配供體的患者。根據國際血液和骨髓移植研究中心於2025年5月發布的《造血細胞移植和細胞治療的最新活動、趨勢和成就》報告，自2020年以來，成人患者接受無關供體不匹配移植的比例加倍。這項技術進步降低了對完美基因匹配的依賴，加快了供體篩選速度，直接提升了移植中心的效率，並透過提高移植的可及性推動了市場成長。

市場挑戰

移植後併發症，尤其是移植物抗宿主疾病（GVHD）的顯著風險，仍是全球造血幹細胞移植市場成長的主要障礙。這種不良反應是指捐贈者免疫細胞攻擊受體健康組織，造成臨床不確定性，並阻礙了此手術的普及。嚴重的併發症和死亡風險使醫護人員和患者都不願選擇移植，尤其是在疾病預後允許採用毒性較小的替代療法的情況下。因此，市場難以將捐贈者數量的成長趨勢轉化為與骨髓惡性腫瘤盛行率相符的實際移植量。

此外，在注重成本的醫療環境下，處理這些併發症帶來的經濟負擔嚴重阻礙了市場擴張。長期免疫抑制治療和反覆住院治療移植物抗宿主疾病（GVHD）對許多醫療系統造成了難以承受的經濟負擔。根據美國衛生資源與服務管理局的數據，CW Bill Young細胞移植計畫在2024年協調了7,550例無關供者造血幹細胞移植。這一數字意味著大量患者需要昂貴且嚴格的術後護理。在報銷模式嚴格的地區，這種營運成本實際上限制了移植機會，儘管供體配型技術取得了進步，但仍阻礙了市場潛力。

市場趨勢

將 CRISPR-Cas9 和基因編輯技術整合到幹細胞療法中，正從根本上重塑市場格局，將焦點從異體移植轉向自體基因修復。這一趨勢利用現有的造血幹細胞移植基礎設施來輸注基因修飾細胞，從而無需進行供體配型，並避免了移植物抗宿主疾病 (GVHD) 的相關風險。這種調查方法正迅速走向商業化，尤其是在血紅蛋白病領域，有效地將移植中心轉變為生物工程療法的中心。正如 Vertex Pharmaceuticals 在 2025 年 11 月發布的「2025 年第三季財報電話會議」中所述，自 Casgevy 基因編輯療法開始應用以來，總合39 名患者接受了治療，這表明該創新治療方法已得到切實應用。

同時，造血幹細胞移植（HSCT）的應用範圍正在擴大，涵蓋自體免疫疾病和非惡性疾病，拓展了傳統腫瘤治療方法。由於安全性提高以及幹細胞重建治癒的潛力，移植中心擴大採用HSCT治療嚴重的自體免疫疾病和血紅蛋白疾病。適應症的擴展正使市場成長不再僅依賴癌症發生率。根據歐洲血液和骨髓移植協會（EBMT）於2025年2月發布的《2023年EBMT造血幹細胞移植和細胞治療報告》，共進行了2558例用於治療非惡性疾病的異基因移植，這證實了相當一部分市場活動集中在良性疾病領域。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球造血幹細胞移植市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（異體移植、自體移植）
  • 根據適應症（白血病、淋巴系統疾病、骨髓瘤等）
  • 透過應用（骨髓移植；周邊血幹細胞移植；臍帶血移植）
  • 依最終用戶（醫院藥局、零售藥局、專科診所）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美造血幹細胞移植市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲造血幹細胞移植市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章 亞太地區造血幹細胞移植市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲造血幹細胞移植市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲造血幹細胞移植市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球造血幹細胞移植市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pluristem Therapeutics Inc
• Lonza Group AG
• Regen Biopharma Inc.
• Bluebird Bio Inc.
• CellGenix GmbH
• Novartis AG.
• Taiga Biotechnologies Inc.
• Takeda Pharmaceutical Company Limited
• Talaris Therapeutics Inc.
• Merck & Co., Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Hematopoietic Stem Cell Transplantation Market is projected to expand from USD 3.09 Billion in 2025 to USD 4.62 Billion by 2031, registering a CAGR of 6.93%. This therapeutic sector involves stem cell infusion procedures designed to rehabilitate bone marrow functionality in individuals suffering from immune deficiencies or hematological malignancies. Key factors fueling this growth include the increasing global frequency of blood cancers like multiple myeloma and leukemia, coupled with technological strides in donor matching that improve allogeneic transplant success rates. Data from the World Marrow Donor Association in 2024 indicates that the global registry network now encompasses over 44.3 million cord blood units and volunteer donors, significantly broadening access to compatible matches for patients without related donors.

Notwithstanding these positive developments, the market faces a substantial obstacle in the form of high post-transplant complication risks, specifically Graft-Versus-Host Disease. In this condition, donor cells aggressively target the recipient's tissues, requiring costly, long-term medical management and negatively affecting the patient's quality of life. Consequently, these clinical risks and associated costs hinder the widespread adoption of the procedure, particularly within healthcare environments that are sensitive to financial constraints.

Market Driver

The rising global prevalence of hematologic malignancies serves as the central catalyst for the uptake of hematopoietic stem cell transplantation. As aggressive blood cancer rates increase, the clinical demand for curative bone marrow reconstitution intensifies, boosting procedural volumes across both established and developing healthcare sectors. The 'Cancer Facts & Figures 2025' report by the American Cancer Society, released in January 2025, forecasted 66,890 new leukemia diagnoses in the United States, highlighting the urgent requirement for effective transplant solutions. This expanding patient base demands a strengthened transplant infrastructure, prompting providers to increase capacity. Additionally, the '2023 EBMT Report on Hematopoietic Cell Transplantation and Cellular Therapies' from the European Society for Blood and Marrow Transplantation in February 2025 noted 47,731 transplants across European centers in 2023, evidencing strong procedural momentum.

In parallel, major breakthroughs in mismatched and haploidentical donor transplantation methods are eliminating traditional impediments to market expansion. The introduction of post-transplant cyclophosphamide protocols has significantly enhanced the safety of utilizing partially matched donors, thereby extending eligibility to patients who previously lacked a fully matched donor option. According to the 'Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy' report published by the Center for International Blood and Marrow Transplant Research in May 2025, the use of mismatched unrelated donors in adult patients has doubled since 2020. This technical progression decreases reliance on exact genetic matches and expedites donor selection, directly augmenting transplant center throughput and stimulating market growth through improved accessibility.

Market Challenge

The significant threat of post-transplant complications, particularly Graft-Versus-Host Disease (GVHD), remains a formidable obstacle to the growth of the Global Hematopoietic Stem Cell Transplantation Market. This adverse reaction, where the donor's immune cells attack the healthy tissues of the recipient, creates clinical uncertainty that discourages the adoption of the procedure. The potential for severe morbidity or mortality often dissuades both healthcare providers and patients from choosing transplantation, particularly when the disease prognosis permits the use of alternative, less toxic treatments. As a result, the market faces difficulties in translating the increasing availability of donors into actual transplant numbers that match the prevalence of hematological malignancies.

Moreover, the financial burden linked to managing these complications severely hampers market expansion in cost-conscious healthcare settings. The requirement for prolonged immunosuppressive therapies and repeated hospital admissions to address GVHD imposes a fiscal strain that is unsustainable for many healthcare systems. Data from the Health Resources and Services Administration indicates that the C.W. Bill Young Cell Transplantation Program coordinated 7,550 unrelated blood stem cell transplants in 2024, a statistic that highlights the substantial number of patients necessitating expensive, rigorous post-operative care. In areas where reimbursement models are restricted, this operational cost effectively limits transplant accessibility, restricting the market's potential despite progress in donor matching capabilities.

Market Trends

The incorporation of CRISPR-Cas9 and gene editing technologies into stem cell therapies is fundamentally reshaping the market by shifting focus from allogeneic replacement to autologous genetic correction. This trend leverages existing hematopoietic stem cell transplantation infrastructure to administer gene-modified cells, thereby removing the need for donor matching and eliminating the risks associated with Graft-Versus-Host Disease. This methodology is rapidly advancing toward commercialization, especially for hemoglobinopathies, effectively transforming transplant centers into delivery hubs for bio-engineered treatments. As noted in the 'Third Quarter 2025 Financial Results' by Vertex Pharmaceuticals in November 2025, a total of 39 patients have received Casgevy gene-edited therapy infusions since its launch, indicating the concrete adoption of this innovative modality.

Concurrently, the application of HSCT is expanding to include autoimmune and non-malignant disorders, thereby diversifying procedural volumes beyond conventional oncological uses. Transplant centers are increasingly utilizing these procedures to address severe autoimmune diseases and hemoglobinopathies, encouraged by enhanced safety profiles and the curative possibilities offered by stem cell reconstitution. This widening of clinical indications effectively separates market growth from a strict reliance on cancer incidence rates. According to the '2023 EBMT Report on Hematopoietic Cell Transplantation and Cellular Therapies' released by the European Society for Blood and Marrow Transplantation in February 2025, 2,558 allogeneic transplants were performed specifically for non-malignant conditions, underscoring the substantial portion of market activity now focused on benign disorders.

Key Market Players

• Pluristem Therapeutics Inc
• Lonza Group AG
• Regen Biopharma Inc.
• Bluebird Bio Inc.
• CellGenix GmbH
• Novartis AG.
• Taiga Biotechnologies Inc.
• Takeda Pharmaceutical Company Limited
• Talaris Therapeutics Inc.
• Merck & Co., Inc

Report Scope

In this report, the Global Hematopoietic Stem Cell Transplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hematopoietic Stem Cell Transplantation Market, By Type

• Allogeneic
• Autologous

Hematopoietic Stem Cell Transplantation Market, By Indication

• Leukemia
• Lymphatic Disorder
• Myeloma
• Other

Hematopoietic Stem Cell Transplantation Market, By Application

• Bone Marrow Transplant; Peripheral Blood Stem Cell Transplant; Cord Blood Transplant

Hematopoietic Stem Cell Transplantation Market, By End User

• Hospital Pharmacy
• Retail Pharmacy
• Specialty Clinics

Hematopoietic Stem Cell Transplantation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hematopoietic Stem Cell Transplantation Market.

Available Customizations:

Global Hematopoietic Stem Cell Transplantation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hematopoietic Stem Cell Transplantation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Allogeneic, Autologous)
  • 5.2.2. By Indication (Leukemia, Lymphatic Disorder, Myeloma, Other)
  • 5.2.3. By Application (Bone Marrow Transplant; Peripheral Blood Stem Cell Transplant; Cord Blood Transplant)
  • 5.2.4. By End User (Hospital Pharmacy, Retail Pharmacy, Specialty Clinics)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Hematopoietic Stem Cell Transplantation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hematopoietic Stem Cell Transplantation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Hematopoietic Stem Cell Transplantation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Hematopoietic Stem Cell Transplantation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Hematopoietic Stem Cell Transplantation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Hematopoietic Stem Cell Transplantation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Hematopoietic Stem Cell Transplantation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Hematopoietic Stem Cell Transplantation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Hematopoietic Stem Cell Transplantation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hematopoietic Stem Cell Transplantation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Hematopoietic Stem Cell Transplantation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Hematopoietic Stem Cell Transplantation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Hematopoietic Stem Cell Transplantation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indication
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hematopoietic Stem Cell Transplantation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Hematopoietic Stem Cell Transplantation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Hematopoietic Stem Cell Transplantation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hematopoietic Stem Cell Transplantation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pluristem Therapeutics Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza Group AG
• 15.3. Regen Biopharma Inc.
• 15.4. Bluebird Bio Inc.
• 15.5. CellGenix GmbH
• 15.6. Novartis AG.
• 15.7. Taiga Biotechnologies Inc.
• 15.8. Takeda Pharmaceutical Company Limited
• 15.9. Talaris Therapeutics Inc.
• 15.10. Merck & Co., Inc

16. Strategic Recommendations

17. About Us & Disclaimer